We’re proud to share the news that our clients have recently achieved FDA approval for their life saving treatment of Duchenne’s muscular dystrophy.
Duchenne’s muscular dystrophy, also known as DMD, is a progressive genetic disease, with a universally fatal outcome in children and no current approved treatment. Over the course of two decades researchers have developed, and through Wrays have patented, a new method of treatment that is safe and effective – successfully arresting the disease’s progression.
In exciting news, the researchers have now achieved approval for the treatment before the United States Food and Drug Administration (FDA). Gaining FDA approval is a difficult, but critical, step in the path to delivery of the treatment to patients.
By working with Wrays and protecting their IP, the researchers were able to attract and make a commercial deal with an international biopharmaceutical therapeutics manufacturer – allowing this desperately needed treatment to become a product soon available to children in need.
(Researchers Sue Fletcher and Steve Wilton with their “genetic patch” machine. Source – ABC News: Rebecca Turner, 20 September 2016)
To read more click here
To view the website for the DMD support group click here